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RNAi oﬀers the opportunity to examine the role in postimplantation development of genes that cause preimplantation lethality
and to create allelic series of targeted embryos. We have delivered constituitively expressed short hairpin (sh) RNAs to pregnant
miceduringtheearlypostimplantation periodofdevelopment andobservedgene knockdownanddefects thatphenocopy thenull
embryo. We have silenced genes that have not yet been “knocked out” in the mouse (geminin and Wnt8b), those required during
earlier cleavage stages of development (nanog), and genes required at implantation (Bmp4, Bmp7) singly and in combination
(Bmp4 + Bmp7), and obtained unique phenotypes. We have also determined a role in postimplantation development of two
transcripts identiﬁed in a diﬀerential display RT-PCR screen of genes induced in ES cells by noggin exposure, Aggf1 a n da nE s t
(GenBank AK008955). Systemic delivery of shRNAs provides a valuable approach to gene silencing in the embryo.
Copyright © 2006 K. Sue O’Shea et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
With the sequencing of the mouse genome [1], there has
been tremendous interest in teasing out the function of “ev-
ery” gene. In the mouse, gene targeting using homologous
recombination in embryonic stem cells (ESC) has provided a
unique opportunity to probe gene function in development
[2], and a number of powerful techniques have been devel-
oped to target genes in temporal or tissue speciﬁc ways. Un-
fortunately, these are time consuming and often require the
development of multiple strains of mice, which then must be
mated to obtain the desired cell-type speciﬁc gene targeting.
The recent application of posttranscriptional gene silencing
using RNA interference (RNAi) to silence target genes has
been an eﬃcient way to study gene function initially in Ce l -
egans and plants, later in mammalian cells in culture, and
recently in embryos.
RNAi is a powerful alternative to traditional gene target-
ing using homologous recombination in ES cells, large scale
mutagenesis,ribozymes,morpholinos,oligonucleotides,and
so forth, for many reasons. Among these are simplicity in
the design of the targeting construct, eﬃciency, and high
throughput (reviewed in [3]). In addition, RNAi oﬀers the
ability to target speciﬁc exons/speciﬁc sequences within a
gene [4], to study gene dosage phenotypes, to target multi-
ple (redundant) genes, to target multiple members of a regu-
latory pathway, and to produce graded levels of knockdown
analogous to allelic series, which is particularly useful in ana-
lyzing the eﬀects of genes that have “threshold” eﬀects rather
than acting as binary on-oﬀ switches. In addition, RNAi may
be particularly useful to avoid the confounding genetic back-
ground eﬀects common to gene targeting using the limited
number of “germ line” ESC lines, and ﬁnally, many other
s p e c i e s( e g ,r a t )c a nb ee m p l o y e d .
Relatively few studies have employed RNAi to study gene
function in the developing embryo. RNAi has been electro-
porated [5, 6] or microinjected into oocytes or early zy-
gotes [7–11], siRNA-transfected ES cells have been used
to create germ line transgenic RNAi mice [12], or all ES
embryos have been generated using tetraploid aggrega-
tion of RNAi-targeted ESC [13]. Delivery, particularly to
postimplantation-staged embryos, continues to be a major
limitation in the widespread application of this important
technology.
Information regarding the prenatal delivery of plas-
mid DNA (pDNA) comes largely from the gene therapy
ﬁeld where in utero gene targeting/therapy has been pro-
posed as a method to treat diseases that aﬀect the devel-
oping embryo [14], which may ultimately be the most ef-
fective means to treat genetic defects. Various routes of
pDNA delivery have been attempted for fetal “gene ther-
apy” including direct injection of the fetus [15–17], injec-
tion into the placenta or umbilical cord [18, 19], injec-
tion into the amniotic cavity [20, 21], or the yolk sac [21],2 Journal of Biomedicine and Biotechnology
typically resulting in the limited transduction of the em-
bryo.
Intravascular delivery of naked DNA is increasingly rec-
ognized as a preferred route to deliver nucleic acids to target
tissues[22]becauseofitssimplicityandeﬀectivenessandbe-
causehighlevelsoftransgeneexpressioncanbeachievedand
sustained (eg, [23]). However, it has required either high-
pressure delivery to produce extravasation [24] or a tourni-
quet to keep the pDNA in place [23]. Tail vein injection has
been employed to silence genes in neonatal [24], and adult
mice [25–28]. Based on these reports, we have recently de-
livered shRNAs to pregnant mice and have observed gene si-
lencing and additional six genes that play important roles in
organogenesis of the early embryo.
MATERIALS AND METHODS
Developmentoftargetingconstructs
Wedevelopedatargetingconstructthatwouldallowustode-
liverasingleplasmidcontainingasmallhairpinRNA(driven
by the constitutively active H1 or U6 promoter) and a ﬂuo-
rochrome reporter driven by the CMV promoter (Figure 1).
The vector backbone is the pCS2 plasmid (from David
Turner),whichcontainstwomultiplecloningsites(MCS)for
insertion of a DsRED and shRNA cassettes. A BamHI/XbaI
fragment that contains the entire DsRed coding region was
removed from pDsRed2-1 (Clontech) and ligated down-
streamoftheCMVpromoterintheﬁrstMCS.TheH1(Gen-
BankAF191547)ortheU6(GenBankX06980)promoterwas
ampliﬁedinPCRwithspeciﬁcprimersandSV129mousege-
nomic DNA was then ligated into the second MCS. Gene-
speciﬁc shRNAs were designed to target Aggf1 (BC052410),
Bmp4 (GenBank X56848), Bmp7 (NM007557), geminin
(AF068780), nanog (AY278951), Wnt8b (NM011720), and
Est1 (AK008955). Each shRNA is a ligated downstream of
the H1 or U6 promoter to yield the ﬁnal expression plasmid.
All sequences are included in the supplemental data.
In addition to conﬁrming that the plasmid reached the
embryonic compartment (DsRed ﬂuorescence), controls in-
clude empty plasmid (pRed) and hairpins containing three
nucleotide substitutions (scrambled hairpins) that corre-
spond to no known mRNA. Blast analysis conﬁrms unique
targeting of the hairpin and that no genes are targeted by the
scrambled hairpin. We monitor target gene expression using
PCR and at the protein level by Western blot or immunohis-
tochemistry when an antibody is available. It is also impor-
tant to monitor additional members of the signaling path-
way, compensatory genes, irrelevant genes, and genes down-
stream of the target. We also monitor the interferon response
gene Oas1 (GenBank AF466823) [29] to determine if our
construct elicits a nonspeciﬁc response.
Tailveininjections
Thesear ecarriedoutinmic easw eha v edescribedpr eviously
[30]. Pregnant females or neonates are placed in a conical
tube (open at the tip for air ﬂow). A small hole is also drilled
into the cap to accommodate the tail. Mice are warmed for
5 minutes using a heat lamp and heating pad, then shRNA
expression plasmids (10μg) diluted in Ringer’s solution are
injectedintothetailvein.Weusea23-Gneedleandavolume
of 200–300μL using a slow steady pressure, usually over 10–
20 seconds for pregnant mice.
Because research in our laboratory has focused on the
early postimplantation period of development, we have typi-
callydeliveredtargetingconstructsatE6.5andautopsiedem-
bryos24hto72hlater.Wehavealsocarriedoutlimitedstud-
ies at midgestation when the placental barrier is most robust,
aswellasonE17.5whenthebarrierthinsanddeliveryshould
be more complete. We examine the extent of DsRed expres-
sion in all embryos using epiﬂuorescence, followed by scan-
ning electron microscopy (SEM), sectioning, immunohisto-
chemistry, Western blotting, and/or PCR. DsRed is typically
expressed throughoutthe earlyembryo, withoutapreference
for a particular tissue type.
Tissueanalysis
Pregnant females and neonatal mice are sacriﬁced by cervical
dislocation followed by rapid dissection of embryos and tis-
sues. Embryos are dissected from the decidua and images are
captured using a Leitz-inverted ﬂuorescence microscope to
determine the extent of DsRed expression. Embryos are then
either embedded in OCT for frozen sectioning or placed in
Trizol for RNA/protein extraction. For SEM or whole mount
immunohistochemistry (IHC), embryos are ﬁxed in 1% glu-
taraldehyde (SEM) or 2% paraformaldehyde (IHC), then
stored at 4◦ prior to additional processing.
For scanning electron microscopy, embryos are dehy-
drated through graded alcohols, washed twice in hexamethyl
disilazane (HMDS), oriented on SEM stubs, and sputter-
coated with gold palladium. They are viewed and pho-
tographed using an Amray 1910 scanning electron micro-
scope.
Sectioning
Unﬁxed sections are cut to determine the pattern of expres-
sion of DsRed and cell type speciﬁc markers using immuno-
histochemistry. Embryos are embedded in OCT and frozen
in hexane cooled over anacetone-dry ice slurry. Sections are
cut at 10μm using a microm cryostat and collected onto
slides.
Immunohistochemistry
Frozen sections or entire embryos are ﬁxed, blocked exten-
sively, followed by primary antibody overnight. The geminin
(sc-13015) and BMP4 (sc-6896) antibodies were obtained
fromSantaCruzBiotechnology(SantaCruz,Calif,USA);the
nanog antibody from Kamiya Biomedical Company (Seattle,
Wash, USA). Whole mount immunohistochemistry was car-
ried out following [29]. Geminin and nanog primary anti-
bodies were used at 1:100, BMP4 at 1:50. Secondary an-
tibody-HRP (1:200, Jackson Immunoresearch Laboratories,K. Sue O’Shea et al 3
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Figure 1: (a) shRNA expression plasmids were constructed using the pCS2 plasmid as the backbone. The DsRed 2.1 coding region was
removed from the pDsRed2-1 vector (Clontech) and cloned downstream of the CMV promoter in the MCSI. The mouse H1 promoter
(1040–1215nt) of the RNAseP/PARP2 promoter, GenBank accession AF191547, was PCR-ampliﬁed from genomic DNA and cloned into
MCSII. Gene-speciﬁc shRNAs (blue region) or scrambled shRNAs (yellow) are then ligated downstream of the H1 promoter. (b) Tail vein
injections were carried out in pregnant mice as we have done previously (29). (c) Embryos are dissected from the uterus, and decidua and
membranes are removed. Transmitted light and ﬂuorescence images of embryos are captured using a Leitz-inverted ﬂuorescence microscope
to determine the extent of DsRed expression and to examine their morphology. A: amnion, Al: allantois, EPC: ectoplacental cone.
West Grove, Pa, USA). Images are captured using a Leitz Flu-
overt or DMIRB microscope then imported into Adobe Pho-
toshop.
PCR
RNAs are extracted from embryos using the Trizol reagent
(Invitrogen, Carlsbad, Calif, USA), quantiﬁed, and DNAsed.
Prior to the reverse transcription (RT) reaction, RNA is sub-
jected to 30 cycles of PCR with β-actin primers to verify
that there is no genomic DNA present. RNAs (1μg) serve
as templates in RT reactions with oligo-dT primers. Gen-
eral PCR conditions are 94◦/3m, 94◦/1m, 51–63◦/1m, and
72◦/2m for 25–35 cycles; however, parameters are optimized
for each primer pair. The products are electrophoresed in
1.5% agarose gels in the presence of ethidium bromide, then
images are scanned into the BioRad Gel Documentation sys-
tem. For quantitative analysis of gene expression, real-time
PCR is performed using the Clonetech Qzyme system on a
BioRad iCycler. Real-time PCR primers were designed and
optimized by Clontech for use in multiplexed assays with
β-actin serving as a reference gene. All reactions are per-
formed in triplicate, and data are analyzed using the 2 −ΔΔ CT
method.
RESULTS
We have delivered shRNA to more than 100 pregnant mice,
and obtained both gene silencing and expression of the
DsRed ﬂuorochrome in embryonic tissues, persisting in
postnatalmice.Wehavecarriedoutanumberofexperiments
to determine if implantation site is correlated with knock-
down. In general, embryos implanted near the vagina ex-
hibited greater knockdown than those near the ovaries. In
most cases, there is knockdown and DsRed is expressed in
embryos. Occasionally (∼ 5% of the injections), there is no4 Journal of Biomedicine and Biotechnology
transfection, likely because injection itself fails due to an in-
suﬃcient amount of DNA entering the circulation.
GemininshRNA
Thegeminingenehasbeenbothdownregulatedandoverex-
pressedinXenopusembryos,reducingorexpandingtheneu-
ral ectoderm ﬁelds, respectively [31]. Geminin is particularly
interesting because, as suggested by its name, the protein has
twofunctions:theC-terminusfunctionsincellcycleprogres-
sion required for diﬀerentiation; the N-terminal is involved
in early neural diﬀerentiation [32]. Despite its provocative
expression in the early neural ectoderm and demonstrated
role in amphibian, Drosophila, and zebraﬁsh development,
there is not yet a knockout of geminin in the mouse.
When a shRNA targeted to geminin was delivered on
E6.5, and embryos were examined one–three days later, we
observed reductions in neural tissue, neural tube closure
defects that typically aﬀected the midbrain, and posterior
neuropore. In early embryos, we observed abnormally ex-
panded nodes and failure of closure of the primitive gut en-
doderm (Figure 2). When we examined geminin expression
in whole mount immunohistochemistry, wild-type embryos
were indistinguishable from control embryos exposed to the
scrambled hairpin both in morphology and in the pattern
of geminin protein expression in the newly induced neu-
ral ectoderm (Figures 2(a), 2(b)). Geminin was present at
slightly higher levels in the anterior neural folds compared
with the posterior region of early somite-staged control em-
bryos (Figures 2(a), 2(b)). There was a slight geminin im-
munoreactivity in the neural ectoderm of some geminin-
targeted embryos (Figure 2(c)); while others expressed vir-
tually no geminin protein (Figure 2(d)). When semiquan-
titative RT-PCR was carried out on RNA isolated from in-
dividual embryos from three litters, there was some vari-
ability in knockdown in the shRNA-exposed embryos, with
two embryos expressing levels similar to control, others ex-
pressing intermediate, low, or no geminin mRNA (Figure 3).
AlthoughgeminintargetinginamphibianandDrosophila
embryos has axis patterning and neural tissue consequences,
there is no information on the early expression of geminin
or targeted deletion of the geminin gene in the early mouse
embryo. Since it is strongly induced by noggin, the observed
neural, node, and endoderm abnormalities are likely due to
the early expression of geminin in these tissues.
NanogshRNAexposure
The nanog gene encodes a varient homeodomain protein
originally identiﬁed in ES cells, where it is required to main-
tain pluripotency and inhibit lineage diﬀerentiation [33].
Targeted deletion in embryos is lethal before implantation
[34], but additional evidence suggested that nanog is ex-
pressed in germ cells and somatic tissues later in develop-
ment [35]; however, its role could not be assessed due to
the early lethality of null embryos. To determine the role
of nanog in later stages of development, we have exposed
21 litters of pregnant mice to shRNA-targeted to nanog via
tail vein injection. We have observed widespread resorp-
tion of nanog-targeted embryos, and in other litters we
haveobservedabnormalitiesofgastrulationandneurulation.
Nanog k n o c k d o w ne m b ry o sa r ec h a r a c t e r i z e db ya x i sa b n o r -
malitieswhicharepresentinearlysomiteembryos,consider-
ably earlier in development than the turning process is initi-
ated, endoderm overgrowth, and neural tube closure defects,
particularly of the midbrain neural folds. Somite segmenta-
tion is also often abnormal, and we have observed abnormal-
ities of cell migration through the primitive streak at gastru-
lation. Figures 4 and 9(b) illustrate some of these malforma-
tions.
In whole mount immunohistochemistry, nanog protein
expression is signiﬁcantly reduced, particularly in the primi-
tive streak of embryos exposed to the nanog shRNA (37). To
correlate phenotype and knockdown, we carried out quanti-
tativePCRonRNAfromindividualnanog-targetedembryos
from an entire litter. Silencing ranged from complete in three
embryosto60%ofwild-typenanog levelsintheleastseverely
aﬀected embryo. The presence of phenotypic abnormalities
correlates strongly with the degree of knockdown, as illus-
trated in Figure 4 by the largely normal appearance of the
embryo from lane 6, compared with the embryo from lane 7.
Somewhat surprisingly, two nanog-shRNA embryos ex-
pressed slightly elevated levels of the Oas1 gene (Figure 5,
lane 15). Bmp4 expression was robust, however, suggesting
that there had not been widespread silencing of nontargeted
genes. Although it is widely employed to monitor oﬀ-target
eﬀects [36], Oas1 is expressed in muscle, brain, and connec-
tive tissue during development [37, 38]. In addition, Oas1
plays a role in cell cycle progression [39], suggesting a need
to monitor additional interferon targets in these studies.
Targetingmultiplegenes:Bmp4,7RNAinterference
Bmp4 has previously been shown to be required in the
gastrulation-staged embryo, where it is important in meso-
derm diﬀerentiation and organization of the primitive streak
[40]. Later Bmp4 plays a role in determining the boundaries
of the neural ectoderm and surface ectoderm [41], with par-
ticularly high levels of BMP4 associated with regions of epi-
dermal ectoderm diﬀerentiation.
WhenacocktailofshRNAtargetedtoBmp4(exons2and
3) was delivered on E6.75 of gestation to pregnant mice, we
observed defects of neural tube closure, allantois develop-
ment, and of heart and axial rotation (Figure 6(b))i nt a r -
geted embryos. The number of primordial germ cells iden-
tiﬁed by alkaline phosphatase staining was also strikingly
reduced. RT-PCR analysis of RNA obtained from individ-
ual Bmp4 shRNA-exposed embryos from one entire litter
identiﬁed only one embryo with any expression of Bmp4
(Figure 7).
Immunohistochemical localization of BMP4 protein was
carried out on sections through shRNA- and pRed (plasmid
lacking the hairpin) exposed embryos, and indicated signif-
icant depletion of BMP4 in targeted embryos [30]. We also
have carried out Western blotting analysis of protein isolatedK. Sue O’Shea et al 5
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Figure 2: Immunohistochemical localization of geminin in control (a) and (b) embryos, and in embryos exposed on E6.5 to geminin shRNA
( ca n dd ) .I nc o n t r o le m b ry o s ,b o t hwi l dtyp e( a )a n de m b ry o se x p o s e do nE 6 . 5t oas c r a m b l e dgeminin hairpin construct (b), the expression
of geminin protein was high in the neural ectoderm of the head folds, although geminin was also expressed in the posterior neural ectoderm
as well (brown reaction product). There is a slight background staining of the allantois and membranes in all embryos (a)–(d). (c) and (d)
Embryos were exposed to the shRNA-targeting geminin, examined and ﬁxed on E7.5 of gestation, then immunohistochemistry to identify
patterns of geminin protein expression was carried out as for (a) and (b) (secondary antibody-HRP). There is low-level geminin protein
remaining in the neural ectoderm in embryo (c) less than that in embryo (d). (e) and (f) Transmitted light images of embryos exposed to the
geminin shRNA on E6.5 and examined on E7.5. (e) Many targeted embryos exhibited axis defects, abnormal expansion of the node (arrow),
and in later embryos, the endoderm of the gut tube often failed to close. (f) Occasionally, the embryonic axis appeared very ﬂattened, and
there was blood within the amniotic cavity. (a), (c), (e), and (f) are sideviews with anterior located toward the left. (b) is a dorso-lateral view,
and (d) is a frontal (coronal) view. A: amnion, Al: allantois, Hf: head folds, WT: wild-type control embryo. Arrows indicate the node.
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Figure 3: (a) Semiquantitative PCR to detect geminin expression in two entire litters of geminin shRNA- exposed embryos. Some embryos
continue to express nearly normal levels of geminin (lanes 1, 4), while others express low (2, 3, 16), intermediate (9, 17–19), or undetectable
(5–8,10–15)levelsofgeminin.Themostadvancedembryosconsistentlyexpressedthehighestlevelsofgeminin.T w oentir elitt ersofgeminin-
targeted embryos were examined; 1–8 and 9–19. −=no RT, + = E9 embryo RNA. (b) Sideview of control and embryos expressing varying
levels of geminin.
from individual embryos exposed to Bmp4 shRNA, where
there was a reduced expression of phospho-Smads 1/5/8,
which are phosphorylated in response to BMP4,7 signaling.
Conventional gene targeting of Bmp4 results in peri-
implantation lethality [40], while on a C57Bl/6 background
embryos live until approximately 26 somite stage [41], and
are characterized by axis elongation abnormalities. The re-
sultsoftheBmp4RNAiphenocopymanydefectsintheBmp4
null embryos [40, 41] including anomalies of axis formation,
primordial germ-cell diﬀerentiation, and neural tube closure6 Journal of Biomedicine and Biotechnology
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Figure 4: (a) Sideviews of two embryos exposed to nanog shRNA. Although the ﬁrst embryo expressed 60% of wild-type levels of nanog
mRNA, developmental defects are minor and include an axis abnormality and a ﬂattened posterior neuropore. When nanog levels are
reduced to 2% of wild type, embryos were more severely aﬀected. The embryo in the right panel is characterized by defects of somite
segmentation, neural tube closure, and abnormalities of endoderm diﬀerentiation. (b) Q-PCR analysis of nanog mRNA expression levels
in individual embryos. Embryos were exposed on E6.5 to the nanog shRNA and examined on E9.0. cDNA from each embryo was run
in triplicate in quantitative PCR with primers to both nanog and β-actin using the Clontech Qzyme system. Levels of β-actin and nanog
expression from nanog shRNA-treated embryos (lanes 2–11) were compared to expression in a control embryo (lane 1). Nanog expression
ranged from 0–60% of control levels. .
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￿
Figure 5: Oas1 PCR. Single embryo RT reactions were subjected to 40 cycles of PCR with primers for Oas1 mRNA (71). Mouse brain RT was
used as a low-level expression positive control (+). Only 2 nanog shRNA embryos were positive for Oas1 expression (one shown, lane15). −
= no cDNA control.
[30]. Many of these are also observed in embryos lacking
Bmpr1a [42].
Because BMP proteins have overlapping functions in de-
velopment, we examined the eﬀects of knocking down mul-
tiple Bmps (Figure 6). We delivered a cocktail of shRNA tar-
geted to Bmp4 + Bmp7,a sw e l la st oBmp7 alone. The Bmp7
shRNA embryos were the least severely aﬀected (Figure 6(c))
with neural tube closure defects, while the Bmp4 + Bmp7
shRNAembryoshadwidelyexpandedneuralfolds,defectsof
rotation, failure of development of posterior structures, and
v e n tra lb o d yw a llc l o s u r ed e f e ct s( Figure 6(d)), a more severe
phenotype than either the Bmp4 shRNA or Bmp7 shRNA
embryos, but strikingly similar to the caudal dysgenesis and
the “massive brains” reported in Xenopus embryos following
morpholino depletion of Bmp2, 4,a n d7[ 43].
DurabilityoftheRNAi
To determine how long knockdown could be maintained, we
carried out tail vein injection of shRNA targeted to Bmp4
on E6.5 and examined neonatal mice. On postnatal days
1–5, neonates were characterized by cystic bladders, had
rudimentary testes or ovaries, and were consistently growth
retarded compared with mice exposed to the pRed con-
trol (Figure 8(a)). Expression of DsRed was maintained in
many tissues in both the mother (including milk) and in the
oﬀspring(Figures8(b),8(c),8(d),8(e),and8(f)).Therewere
also anomalies of the subventricular neural stem cell zone
(SVZ; Figures 8(b), 8(c)) which depends on noggin-BMP4
signaling [44].
Multipletargets,multiplephenotypes
Although there are considerable data available regarding the
role of secreted signaling molecules in the initial events of
neuralinduction,verylittleisknownregardingthegenesthat
bridge the process of neural induction and neural diﬀeren-
tiation. To identify novel genes that mark the earliest neu-
ral ectoderm, we carried out a diﬀerential-display RT-PCR
screen of genes induced in mouse embryonic stem (ES) cells
by noggin protein. From this screen, we selected several tran-
scripts that were expressed in early embryos just after induc-
tion. Based on their expression proﬁles, we selected several
candidates for RNAi silencing. Two of these had not previ-
ouslybeenexaminedduringdevelopment.Duringthecourse
of our work, Aggf1 (angiogenic factor with Gpatch and FHA
domains 1) was identiﬁed as an angiogenic factor mutated in
human disease [45], but no information is available about its
expression or role in development. Initial in situ hybridiza-
tion studies indicated that Aggf1 i se x p r e s s e da th i g hl e v e l si n
thedistalepiblast,especiallyintheposteriorepiblastonE7.5.
At later stages it is expressed in the neural ectoderm. shRNAK. Sue O’Shea et al 7
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Figure 6: Eﬀects of Bmp shRNA. (a) Scanning electron microscopy
(SEM) view of a control embryo illustrating completed neural tube
closure in the forebrain (F) region; the posterior neuropore (pnp)
has not yet been closed. (b) Bmp4 shRNA-exposed embryo with
widely open anterior neural folds (arrows) and posterior neuropore
(lower black arrow). (c) SEM view of a Bmp7 shRNA-exposed em-
bryo.Boththemidbrain(arrows)andtheposteriorneuropore(pnp
arrow) are widely open, but the body axis defects characteristic of
Bmp4 shRNA and Bmp4 + 7 shRNA embryos were not present. (d)
Ventrolateral SEM view of a compound Bmp4 + Bmp7 shRNA em-
bryo. The cephalic neural folds are unfused (arrows) and the poste-
rior region is rudimentary (∗). 1: ﬁrst branchial arch, A: amnion, F:
forebrain, H: heart, pnp: posterior neuropore.
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Figure 7:RT-PCRanalysisofindividualBmp4shRNA-exposedem-
bryos from one entire litter. The positive control (+) is from an em-
bryo exposed to pRed control vector alone. Pregnant dams were in-
jected on E6.5 and RNA extracted from embryos on E9.0.
targeted to Aggf1 produced a lethal phenotype at E7.5. In
these embryos, the ectoderm delaminated, and blood was
often present within the amniotic cavity. Given its role in
vessel formation, it is not surprising that we also observed
implantation defects in shRNA-exposed embryos. Rare em-
bryos that survived to E8.5 were characterized by focal hem-
orrhages and neural tube defects that aﬀected midbrain and
posterior neuropore (Figure 9(c)).
Est1 was identiﬁed twice in the diﬀerential display as-
say. Initial in situ hybridization localization studies indicate
that it is expressed in the early epiblast, preconﬁguring the
primitive streak, in the node, later in the neural ectoderm.
Targeting Est1 produced a severe neurulation phenotype,
embryos with open neural folds, defects of embryonic rota-
tion, and diﬀerentiation of posterior structures, reminiscent
of genes involved in L-R axis patterning (Figure 9(d)).
A number of Wnt family members were also identiﬁed in
this screen. Because Wnt8b had not previously been silenced,
we delivered shRNA targeted to Wnt8b to pregnant dams on
E6.75. Resulting embryos were characterized by axis elon-
gation defects (Figure 9(f)). These embryos also had neural
tube closure anomalies and defects in closure of the endo-
derm.
We have delivered shRNA targeted to Wnt8b, Bmp4,
Bmp7,Bmp4+Bmp7,geminin,nanog,andtotwoEstsidenti-
ﬁed in a diﬀerential display RT-PCR screen and observed
speciﬁc targeting and unique phenotypes (Figure 9). These
studies have also identiﬁed a previously unsuspected role
for nanog in gastrulation and also in somite organization
(Figures 4, 9(b)). Overall, we believe that these results are
important and valid for a number of reasons. One, we have
targeted multiple genes and observed unique phenotypes.
These include Bmp4 (phenocopies the Bmp4 null embryos,
as far as is possible to determine due to early lethality of the
null embryos), Bmp7 alone, Bmp4 + Bmp7, Wnt8b, nanog,
Aggf1, and Est1. Two, in each case where an antibody is avail-
able to the protein (BMP4, nanog, geminin) or to the down-
stream signal transduction cascade (PhosphoSmad1, 5, 8),
we have demonstrated knockdown in “individual” embryos.
Three, in cases where an antibody is not available, we have
demonstrated unique phenotypes and knockdown by PCR.
Four, these data also demonstrate that we can knock down
multiple targets, for example, Bmp7 and Bmp4, and identify
an additive phenotype.
DISCUSSION
With genome-wide gene sequencing data now available,
there is increased interest in systematically manipulating
“all” the genes of the mouse to understand their roles in de-
velopment and disease. Many new tools to manipulate gene
function have been developed including ribozymes, microR-
NAs, DNAzymes, as well as a number of methods for post-
transcriptional gene silencing such as morpholinos (review
[46]), antisense oligos (review [47]), and RNAi (review [3]).
RNAi is typically more robust than antisense oligos or mor-
pholinos in embryos [48, 49], and morpholinos have the
additional problem that the translational start site must be
known, so uncharacterized genes (such as Ests) cannot be
targeted.
RNAi may be particularly appropriate in targeting a de-
velopmental disease such as Down’s syndrome/trisomy 21
once critical duplicated genes are identiﬁed, and may also be
eﬀective in targeting upstream pathways in metabolic disease
to limit disease progression, or in silencing activating gene
mutations, such as in the FGF receptor-2 which produces8 Journal of Biomedicine and Biotechnology
(a) (b) (c)
(d) (e) (f)
Figure 8: Longevity of the RNAi. (a) Day 10 neonatal mice (PN10) obtained from litters exposed on E6.5 to the Bmp4 shRNA (left) or to
pRed (no hairpin plasmid) control (right). Bmp4 shRNA mice were consistently developmentally delayed and lacked testis or ovaries. (b)
and (c) Coronal sections through the lateral ventricles of PN3 mice exposed on E17.5 to pRed control (b) or to Bmp4 shRNA (c). In addition
to the obvious anomalies of the subventricular zone and ventricle, neural stem cells obtained from the Bmp4 shRNA mice fail to diﬀerentiate
normally. (d)–(f) illustrate the persistent expression of DsRed in liver (d), lung (e), and spinal cord (f) in neonates exposed to Bmp4 shRNA
on E6.5.
craniosynostosis [50]. Systemic delivery will also be applica-
ble to diseases that aﬀect tissues with open circulations, as
well as diseases in which the blood brain barrier is opened
such as Duschenne muscular dystrophy, certain brain tu-
mors, in aging, and in multiple sclerosis (review [51]).
These studies have identiﬁed unsuspected roles in devel-
opment for several genes. In the case of nanog,w h i c hi nn u l l
embryos is lethal at early cleavage stages of development, we
have identiﬁed a role in gastrulation, neurulation, and in en-
doderm diﬀerentiation. There is not a report of a knockout
of the geminin gene in the mouse, and it will be of particu-
lar interest to study carefully the characteristics of the neural
tissue in targeted embryos, as well as the characteristics of
the node. Neither is there a published report of a Wnt8b
knockout, but many of the defects observed in this study
are similar to those present in other Wnt null embryos. For
example, Wnt3a null embryos have similar severe posterior
truncations [52]. The use of RNAi directed against individ-
ual Wnt mRNAs should allow rapid analysis of speciﬁc Wnt
functions. In addition, since Wnts may compensate for each
other, masking functions in single-gene knockouts, combi-
natorial Wnt RNAi should help elucidate overlapping rela-
tionships between the Wnts. Delivery of shRNA to pregnant
dams has also provided an opportunity to rapidly determine
if there was a role in early embryos for novel genes identiﬁed
in a diﬀerential display RT-PCR screen. A role for Aggf1 in
later aspects of vasculogenesis was described previously [45],
and given its role in vessel development, it is not surprising
that targeting Aggf1 aﬀected the implantation process.
The ability to target multiple genes with overlapping ex-
pression and function, as in the case of Bmp4/7 [53], is an
importantimprovementovertraditionalknockoutsinwhich
mutations in multiple genes are obtained by breeding. In the
future, it will be important to target multiple genes using a
single plasmid containing multiple hairpins, rather than the
cocktail we have employed to target Bmp4 and Bmp7.
To date, study of the placental transport of plasmid DNA
has come largely from attempts to deliver pDNA for in utero
gene therapy, which have produced conﬂicting results. Thus,
when pDNA complexed with liposomes was delivered by in-
travenous injection of pregnant mice on E2.5, 5.5, 8.5, 11.5,
or 14.5, no plasmid DNA was detected in fetuses exposed on
E2.5 or E5.5, while embryonic expression peaked with deliv-
ery on E8.5, compared with E11.5 or E14.5. ”All” embryos
treated on E8.5 expressed the plasmid, with sustained ex-
pression at 40 days postinjection [54]. However, it has also
been reported that DNA-liposome complexes were trapped
in the visceral endoderm prior to placenta development on
E11.5 [55]. Others have also reported hemodynamic trans-
fer of genes to the fetal compartment, however. For example,K. Sue O’Shea et al 9
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Figure 9: Control- and Gene-targeted embryos: nanog, geminin, Aggf1, and Est1. (a) Control embryo. Sideview of an embryo exposed
to pRed plasmid (no hairpin) on E6.5 and examined on E8.5, illustrating the normal appearance of the head folds (Hf), somites, and
unturned body axis. (b) Nanog shRNA. Embryo exposed on E6.5 to shRNA targeting nanog, illustrating the typical lack of development of
the head folds (Hf) and posterior region in the tail bud (T). Somites have also failed to segregate normally. (c) and (d) We carried out a
diﬀerential display RT-PCR screen of genes induced in D3 ESC by noggin exposure, then targeted two using tail vein injection of shRNAs.
(c) Aggf1-targeted embryos failed to implant normally and the primitive ectoderm often delaminated into the amniotic cavity. Hemorrhages
are present within the embryo; there are striking abnormalities of turning and posterior development in the rare embryo that survived to
E8.5. (d) Est1-targeted embryo. There were anomalies of primitive streak organization in these embryos. They also often failed to turn to
adopt the fetal position and exhibited abnormalities of the node. (e) pRed control. Sideview of an E8.5 pRed (no hairpin) control. This
embryo is beginning the turning process, the body axis is elongated, neural folds are fused in the anterior (head fold, Hf) region, although
the posterior neuropore remains open in the tail bud (T). (f) Wnt8b-targeted embryo illustrating the shortened axis and open neural folds
typical of these embryos. (g) and (h) Geminin shRNA. An embryo exposed to geminin shRNA on E6.5 and examined on E8.5. There are very
characteristic midbrain (upper arrows) and posterior neuropore (lower arrow in (g)) defects in these embryos, which exhibit widespread
DsRed ﬂuorescence (H). All embryos are oriented with anterior toward the left. Al: allantois, H: heart, Hf: head folds, T: tail bud. Arrows
indicate open neural folds.
intravenous delivery of plasmid DNA to pregnant mice on
E9.5 successfully immunized the fetuses against HIV-1 and
inﬂuenza [56]. We have avoided carriers since liposomes are
often immunogenic, are generally less eﬀective in serum, and
can be toxic to both the embryo and the pregnant female
[55].
Although we have obtained widespread expression of
our construct, a number of improvements and alternative
approaches can be considered. It would be possible to in-
crease the amount of DNA injected, although 5μg plasmid
DNA was optimal (saturating) and > 25μg/mouse was toxic
[57, 58]. Other studies have shown that transfection eﬃ-
ciency is not determined by volume or rate, but the amount
of DNA delivered, with highest expression achieved with
1000ng/mouse (23). Given the ∼ 1.6mL blood volume of
an 18g mouse and observations that there is less degradation
of pDNA in a larger volume of carrier [58], increasing the
volume delivered would be an option. Rate of injection—5
seconds is better than 30 [24, 58]—could also be considered,
but very rapid injection can be lethal.
Despite careful breeding, the developmental stage of in-
dividual embryos at the time of exposure to shRNAs cannot
be known precisely, and may account for some of the vari-
ability in our results. Alternatives include using exo-utero
surgery of midgestation embryos with injection of shRNAs
and electroporation [49]. For early postimplantation stages
when exo-utero surgery is not applicable, whole embryo cul-
ture presents another option [59]. Better promoters and bet-
ter control of CRE expression in the early embryonic com-
partment will allow the development of hybrid approaches
to speciﬁcally, inducibly silence gene expression in a par-
ticular tissue/cell type (eg, 61). Interestingly, the oocyte-
restricted ZP3 promoter was recently employed to drive ex-
pression of dsRNA targeted to the Mos gene, recapitulating
the null phenotype, with spontaneous parthenogenetic ac-
tivation [60]. These and other recent investigations suggest
that it will be possible to target RNAi to particular cells or
tissues.
One drawback to tail vein injection is the loss of plasmid
DNA to the female and unintended transfection of maternal10 Journal of Biomedicine and Biotechnology
Table 1
Aggf1 tttacttcgaccatgacttgca tttaTttcgCccatgacttgTa
gctcgtcctttctatcgaggc gcGcgtcctGtctatcgagTc
Bmp4 cagtccatgattcttggga cagtcAatgaGtcttgTga
ccttcagaaaccggtcggc cAttcagaaTccggtAggc
Bmp7 tccatctccgtagtatccg tccGtctccgCagtatTcg
ttcgacgacagctctaatg ttcCacgaTagctctCatg
Est1 cccgaacgatatttggtgtga ccGgaacgaGatttggtgtTa
caagacgacgtgacaattcca caCgacgaTgtgacaattcTa
Geminin tcatgtacacggcctagcat tAatgtacCcggcctagAat
attcctgactatccggtga atCcctgactatAcggcga
Nanog ttctgggaacgcctcatcaatgc ttcCgggaacAcctcatcaTt
ggaagcagaagatgcggactgt ggaTgcagaCgatgTggactgt
Wnt8b atgtacaccctgactagaaactgcagcct aGgtacaccAtgactagatgcagAct
gtccgctgcgagcagtgccgccgg gGccgctAcgagTagtgccgccgA
PCR Primers
Gene Forward 5 -3  Reverse 5 -3 
Bmp4 ctcccaagaatcatggactg aaagcagagctctcactggt
Geminin gagaaaatgagttgccaaaagg ccacagcttgaagtctgagatg
Nanog agggtctgctactgagatgctctg atcttctgcttcctggcaag
Oas1g atggtagtatcaataagaagc gcatagacagtgagtagctcc
actin ttgctgacaggatgcagaaggaga actcctgcttgctgatccacatct
tissues. Since the liver has an expandable circulation and is
easily transfected using intravenous delivery, it is important
to monitor liver function in pregnant females and neonates.
Obviously, when the targeted gene is important in maternal
tissues, this is a larger concern that must be constantly mon-
itored. Additional experiments might therefore include tar-
geting of a nonessential protein such as EGFP in the GFPU
mouse [61] which has no known downstream targets, nor
have there been deleterious eﬀects of EGFP cleavage prod-
ucts. It would be possible to mate hemizygous GFPU mice to
determine if there are any deleterious eﬀects that are trans-
mitted to the nontargeted +/+ embryos. It would also be
useful to target a gene expressed only in male embryos, so
that female littermates would serve as a control for oﬀ-target
and/or maternal eﬀects.
It is impractical to carry out microarray analyses of indi-
vidual, targeted embryos to determine speciﬁcity of target-
ing, although in previous studies when the targeting con-
struct was speciﬁc, RNAi signatures were unique and highly
speciﬁc for the target gene [62, 63]. More detailed analy-
sis can also be carried out to verify the presence of speciﬁc
mRNA cleavage products using 5  RACE, PCR to identify
the cleavage fragments with sequencing [64]. It has gener-
ally been assumed that early development in the embryo
is incapable of mounting a full interferon response [65],
yet interferon responsive genes such as fragilis are expressed
during very early postimplantation development [66]. Since
Oas1 may have additional roles in development, monitoring
other interferon-responsive genes would also be appropriate
in these studies. Recent evidence also suggests that shRNA
expression can competitively inhibit endogenous miRNA
function via exportin 5 [67], although inclusion of scram-
bled hairpin constructs should control for this eﬀect. Much
remains to be understood about this technique, particularly
regarding transport, uptake, and expression in the embryos
and fetuses.
Sincetheﬁrsttransgenicmousewasdevelopedin1980by
pronuclearinjectionofDNA[68],therehavebeenmajorim-
provements to the technological base for mouse functional
genomics, and RNAi promises to be a powerful new addition
to that tool set.
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